| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 61 | Strain of Lactobacillus gasseri | US09600165 | 2000-09-22 | US06596530B1 | 2003-07-22 | Katsunori Kimura; Haruhisa Hirata; Yasuhiro Koga |
| A food or drink product with a disinfection property of Helicobacter pylori and/or a protection property against infection with H. pylori, comprising as the effective ingredient Lactobacillus gasseri OLL 2716 (FERM BP-6999) with a high disinfection potency of H. pylori. The food or drink product prepared by using the lactic acid bacterium, such as acid milk and the like, is suitable for long-term ingestion as a food or drink product with a disinfection property of H. pylori and/or a protection property against infection with H. pylori. | ||||||
| 62 | Acetobacter and gluconacetobacter strains and their metabolites for use in inhibiting xanthine oxidase | US14829868 | 2015-08-19 | US09867857B2 | 2018-01-16 | Siao-Jhen Cheng; Yen-Lin Chen; Hsun-Yin Hsu; Kai-Ping Chen; Chiao-Ming Liao; Yi-Jen Yech |
| A method for inhibiting xanthine oxidase and for reducing uric acid levels using a pharmaceutical composition or a food product obtained by culturing Gluconacetobacter hansenii or Acetobacter pasteurianus in a medium. Also disclosed is a pharmaceutical composition and a food product that each include a metabolite of Gluconacetobacter hansenii or Acetobacter pasteurianus for reducing uric acid levels in a subject and methods for producing the pharmaceutical composition and the food product. | ||||||
| 63 | COMPOSITIONS FOR THE INHIBITION OF GIARDIA LAMBLIA | US15501587 | 2015-08-10 | US20170216415A1 | 2017-08-03 | Luis G. BERMUDEZ-HUMARAN; Thibault ALLAIN; Isabelle FLORENT; Philippe LANGELLA; Philippe GRELLIER; Marie-Agnes TRAVERS; Bruno POLACK |
| The present invention relates to a composition exhibiting a bile-salt hydrolase activity for its use for the treatment or the prevention of giardiasis, said composition comprising a bile-salt hydrolase (BSH) enzyme, a bacterium able to secrete a BSH, a recombinant host cell able to secrete a BSH, or a combination thereof. The present invention also relates to the use of a composition exhibiting a BSH activity for the treatment or the prevention of giardiasis, and to a pharmaceutical composition or a food composition comprising, as an active principle, a BSH, a lactic acid bacterium able to secrete a BSH, or a recombinant host cell able to secrete a BSH. | ||||||
| 64 | Mixture of lactic bacteria for the preparation of gluten free baked products | US14622587 | 2015-02-13 | US09560854B2 | 2017-02-07 | Giammaria Giuliani; Anna Benedusi; Raffaella Di Cagno; Maria De Angelis; Antonella Luisi; Marco Gobbetti |
| The present invention concerns a mixture of lactic bacteria for yeasting of gluten-free baked products. Particularly, the invention concerns the use of “natural yeast” based on selected lactic bacteria as yeasting agent for the production of gluten-free bread, with improved sensory and nutritional property, designed for celiac patients feeding. | ||||||
| 65 | Method for culturing lactic acid bacterium and method for producing fermented milk | US13260249 | 2010-03-26 | US09426999B2 | 2016-08-30 | Masayuki Kamijo |
| First, prepared is a whey degradation medium to which a protease, yeast extract, and the like are added. Further, polyoxyethylene sorbitan monooleate or propylene glycol monooleate is added to the whey degradation medium. The whey degradation medium is inoculated with bacteriocin-producing lactic acid bacterium and the lactic acid bacterium is cultured while the whey degradation medium is maintained at pH of 4 to 5. After the completion of the culture, the whey degradation medium (culture solution) is centrifuged to thereby separate therefrom a concentrated cell suspension containing the lactic acid bacterium in a concentrated form. The concentrated cell suspension has very low antibacterial activity (several tens AU or less). Then, by adding the concentrated cell suspension to a yogurt mix and fermenting the same, it is possible to produce yogurt containing the bacteriocin-producing lactic acid bacterium without any delay in the fermentation. | ||||||
| 66 | MIXTURE OF LACTIC BACTERIA FOR THE PREPARATION OF GLUTEN FREE BAKED PRODUCTS | US14622587 | 2015-02-13 | US20150216185A1 | 2015-08-06 | Giammaria GIULIANI; Anna Benedusi; Raffaella Di Cagno; Maria De Angelis; Antonella Luisi; Marco Gobbetti |
| The present invention concerns a mixture of lactic bacteria for yeasting of gluten-free baked products. Particularly, the invention concerns the use of “natural yeast” based on selected lactic bacteria as yeasting agent for the production of gluten-free bread, with improved sensory and nutritional property, designed for celiac patients feeding. | ||||||
| 67 | LIPID METABOLISM AND/OR SUGAR METABOLISM IMPROVER CONTAINING LACTIC ACID BACTERIUM OR TREATMENT PRODUCT THEREOF | US14363150 | 2012-12-06 | US20140322172A1 | 2014-10-30 | Futoshi Nakamura; Nobuhisa Ashida; Yu Ishida; Shigeru Fujiwara |
| This invention provides the use of a microorganism capable of improving both lipid metabolism and sugar metabolism. Specifically, the invention relates to: a lipid metabolism and/or sugar metabolism improver comprising, as an active ingredient, a bacterial cell selected from bacteria belonging to the genus Lactobacillus and the genus Bifidobacterium, a treated product of the bacterial cell, or a mixture thereof, having dual-agonistic activities to peroxisome proliferator activated receptor (PPAR)α and peroxisome proliferator activated receptor (PPAR)γ; to a food or a beverage comprising the improver; and to a pharmaceutical composition comprising the improver. | ||||||
| 68 | Compositions for the vaginal and oral administration of Lactobacillus and uses thereof | US13821431 | 2011-09-13 | US08846027B2 | 2014-09-30 | Herbert Kiss; Konrad J. Domig; Wolfgang Kneifel; Helmut Viernstein; Frank M. Unger |
| The present invention relates to compositions for the oral and vaginal administration of human Lactobacilli and uses thereof for physiologic restoration of the vaginal flora, physiologic maintenance of Lactobacillus flora in pathologic deficiency to produce Lactobacilli, treatment of asymptomatic bacterial vaginosis and prevention of preterm delivery caused through bacterial vaginosis. | ||||||
| 69 | Cheese capable of disinfecting Helicobacter pylori | US10510497 | 2003-04-11 | US08758841B2 | 2014-06-24 | Shunji Hayashi; Shigeru Aizawa; Naoki Taketomo; Tadashi Nakatsubo; Noriaki Matsunaga; Katsunori Kimura |
| Natural cheese which comprises a lactic acid bacterium belonging to Lactobacillus gasseri having a disinfection potency against Helicobacter pylori, and a method for producing the natural cheese. | ||||||
| 70 | POLYBACTERIAL PREPARATION WITH HEALTH BENEFITS: ANTIOXIDANT EFFECT, REDUCTION OF CHOLESTEROL CONCENTRATION, ANTI-INFLAMMATORY IMMUNOMODULATING EFFECT AND RELEASE OF BIOACTIVE PEPTIDES INHIBITING ANGIOTENSIN-CONVERTING ENZYME | US14114851 | 2012-05-03 | US20140072544A1 | 2014-03-13 | Zhechko Dimitrov; Michaela Michaylova |
| This invention relates to polybacterial probiotic preparation, which includes new strains of lactic acid bacteria Lactobacillus gasseri 7/12 NBIMCC No. 8720, Lactobacillus plantarum F12 NBIMCC No 8722 and Lactobacillus helveticus A1, NBIMCC No 8721 and has the following set of properties: antioxidant, hypocholesterolemic effect, anti-inflammatory immunomodulating effect, ability to release bioactive peptides that inhibit angiotensin-converting enzyme (ACE), which is responsible for the high blood pressure. The object of invention is also the described probiotic strains of lactic acid bacteria and the developed bacterial products with useful properties. The incorporated probiotic strain Lactobacillus gasseri 7/12 NBIMCC No. 8720, has a number of properties: strong adhesion to the epithelial layer of the colon, the ability for reduction of cholesterol and anti-inflammatory effects by reducing the levels of proinflammatory cytokine interleukin-8. The invention relates to the use of strains of lactic acid bacteria and bacterial agents in the production of starter cultures, food additives, food, functional products and pharmaceutical preparations intended to influence the health of humans and animals. | ||||||
| 71 | METHOD FOR ENHANCING PPARy EXPRESSION | US13922499 | 2013-06-20 | US20130344043A1 | 2013-12-26 | WEI-CHIH SU; HSIANG LING CHEN; CHUN-HSIEN HUANG; HSIAO-LI WU; PEI-YU TSAI |
| The present invention provides a method for enhancing PPARγ expression, comprising administering a subject in need thereof an effective amount of Lactobacillus gasseri PM-A0005, which was deposited under Budapest Treaty in the China Center for Type Culture Collection (CCTCC), China with Deposition No. M 207039. | ||||||
| 72 | Method for screening human ABO blood group-binding lactobacilli | US12987518 | 2011-01-10 | US08465933B2 | 2013-06-18 | Tadao Saito; Yasushi Kawai; Hideaki Uchida; Katsunori Kimura; Kakuhei Isawa; Keisuke Furuichi |
| Lactobacillus screening methods were carried out using surface plasmon resonance spectrums and human intestinal mucin and blood group antigens as probes. A trial to set selection criteria in the above-mentioned methods of screening for lactobacilli was made to adapt the methods to mass screening, and it was discovered that lactobacilli compatible with ABO blood groups can be screened by setting 100 RU as a criterion for judging bacterial binding under certain conditions. Using 238 lactobacillus strains, the above-mentioned screening methods and tests to judge their compatibility for the use of yogurt production were carried out, to at long last specifically discover bacillus strains compatible with blood groups A, B, and O. | ||||||
| 73 | Human ABO blood group-binding lactobacilli | US11720462 | 2005-12-01 | US07897374B2 | 2011-03-01 | Tadao Saito; Yasushi Kawai; Hideaki Uchida; Katsunori Kimura; Kakuhei Isawa; Keisuke Furuichi |
| Lactobacillus screening methods were carried out using surface plasmon resonance spectrums and human intestinal mucin and blood group antigens as probes. A trial to set selection criteria in the above-mentioned methods of screening for lactobacilli was made to adapt the methods to mass screening, and it was discovered that lactobacilli compatible with ABO blood groups can be screened by setting 100 RU as a criterion for judging bacterial binding under certain conditions. Using 238 lactobacillus strains, the above-mentioned screening methods and tests to judge their compatibility for the use of yogurt production were carried out, to at long last specifically discover bacillus strains compatible with blood groups A, B, and O. | ||||||
| 74 | LACTIC ACID BACTERIUM HAVING EFFECT OF LOWERING BLOOD URIC ACID LEVEL | US12745006 | 2008-11-27 | US20100316618A1 | 2010-12-16 | Hiroshi Tsuboi; Noriko Kaneko; Akina Satou; Akinori Kume; katsunori Kimura |
| The present invention provides lactic acid bacteria which are suitable for use for dietary products and pharmaceuticals, and which can suppress the increase of blood uric acid level.Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2922, were found. | ||||||
| 75 | LACTIC ACID BACTERIA ISOLATED FROM MOTHER'S MILK WITH PROBIOTIC ACTIVITY AND INHIBITORY ACTIVITY AGAINST BODY WEIGHT AUGMENTATION | US12376368 | 2007-05-14 | US20100203025A1 | 2010-08-12 | Ji Hee Kang; Byeung Il You; Sung Il Yun; Han Oh Park |
| The present invention relates to a lactic acid bacterium isolated from human mother's milk, more precisely a Lactobacillus gasseri BNR17 strain that is isolated from Korean mother's milk and has excellent probiotic activity including acid resistance, bile acid resistance and antimicrobial activity and weight gaining inhibitory effect as well Again, the Lactobacillus gasseri BNR17 of the present invention has excellent acid resistance, bile acid resistance, enteric absorption activity and antimicrobial activity against pathogenic microorganisms, in addition to the weight gaining inhibitory effect by synthesizing indigestible polysaccharides from monosaccharides included in food taken and releasing the synthesized polysaccharides out of the body. Therefore, the strain of the invention, owing to such beneficiary effects, can be effectively used not only for the production of fermented milk, other fermented food products and animal feeds but also for the production of live cell products and food additives for preventing weight gaining. | ||||||
| 76 | Cheese capable of disinfecting helicobacter pylori | US10510497 | 2003-04-11 | US20050163888A1 | 2005-07-28 | Shunji Hayashi; Shigeru Aizawa; Naoki Taketomo; Tadashi Nakatsubo; Noriaki Matsunaga; Katsunori Kimura |
| Natural cheese which comprises a lactic acid bacterium belonging to Lactobacillus gasseri having a disinfection potency against Helicobacter pylori, and a method for producing the natural cheese. | ||||||
| 77 | Food or drink product with a disinfection property of helicobacter pylori | US10366401 | 2003-02-14 | US20030161820A1 | 2003-08-28 | Katsunori Kimura; Haruhisa Hirata; Yasuhiro Koga |
| A food or drink product with a disinfection property of Helicobacter pylori and/or a protection property against infection with H. pylori, comprising as the effective ingredient Lactobacillus gasseri OLL 2716 (FERM BP-6999) with a high disinfection potency of H. pylori. The food or drink product prepared by using the lactic acid bacterium, such as acid milk and the like, is suitable for long-term ingestion as a food or drink product with a disinfection property of H. pylori and/or a protection property against infection with H. pylori. | ||||||
| 78 | LACTIC ACID BACTERIUM-CONTAINING FAT OR OIL COMPOSITION AND METHOD FOR MANUFACTURING SAME | US15577119 | 2016-05-31 | US20180206540A1 | 2018-07-26 | Hiroaki ASHITANI; Toshiyuki KOYAMA; Yoko USAMIKRANK; Tomokazu ISHIZUKA; Keiji TADOKORO; Yusuke KABUKI; Yasunori YONEJIMA; Keiko HISA |
| By adding a viable lactic acid bacterium to a fat or oil composition, the present invention has succeeded in producing a lactic acid bacterium-containing fat or oil composition that has a high viability of the lactic acid bacterium and an excellent resistance to acids. By adding lactic acid bacteria powder or a chocolate with a high lactic acid bacterium concentration to a chocolate dough after tempering and before molding, moreover, the present invention has succeeded in producing a lactic acid bacterium-containing chocolate including a viable lactic acid bacterium by a simple producing method. Thus, provided is a lactic acid bacterium-containing chocolate with high palatability that contains a viable lactic acid bacterium. | ||||||
| 79 | Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation | US14537565 | 2014-11-10 | USRE46912E1 | 2018-06-26 | Ji Hee Kang; Byeung I. You; Sung I. Yun; Han O. Park |
| The present invention relates to a lactic acid bacterium isolated from human mother's milk, more precisely a Lactobacillus gasseri BNR17 strain that is isolated from Korean mother's milk and has excellent probiotic activity including acid resistance, bile acid resistance and antimicrobial activity and weight gaining inhibitory effect as well. Again, the Lactobacillus gasseri BNR17 of the present invention has excellent acid resistance, bile acid resistance, enteric absorption activity and antimicrobial activity against pathogenic microorganisms, in addition to the weight gaining inhibitory effect by synthesizing indigestible polysaccharides from monosaccharides included in food taken and releasing the synthesized polysaccharides out of the body. Therefore, the strain of the invention, owing to such beneficiary effects, can be effectively used not only for the production of fermented milk, other fermented food products and animal feeds but also for the production of live cell products and food additives for preventing weight gaining. | ||||||
| 80 | LACTOBACILLUS SP. STRAIN HAVING ABILITY TO INHIBIT PROLIFERATION OF VIRGINAL PATHOGENIC MICROORGANISMS | US15566352 | 2016-03-24 | US20180117100A1 | 2018-05-03 | Gwang Pyo KO; Hyun Ju YOU; Bo Mi KWON |
| The present invention relates to a novel Lactobacillus sp. isolation strain having an activity to inhibit the growth of vaginitis pathogens, and a pharmaceutical composition, a health functional food, and a cleansing product, comprising the strain as an active ingredient. Therefore, the present invention exhibits an effect of inhibiting the growth of Sneathia spp. pathogens associated with the infection with human papillomavirus (HPV) and the incidence of bacterial vaginitis, Gardnerella vaginalis as a vaginitis pathogen, and Candida albicans as a causative bacteria of Candidal vaginitis, and an effect of recovering and maintaining the vaginal microflora, and thus can be used for the prevention and treatment of female vaginitis. | ||||||
QQ群二维码
意见反馈
意见反馈